Identification
NameAluminum hydroxide
Accession NumberDB06723
TypeSmall Molecule
GroupsApproved
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Structure
Thumb
Synonyms
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
External IDs NSC-664400
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alu-tab Tab 600mgTablet600 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada
Aluminum HydroxideLiquid320 mg/5mLOralRugby2005-02-01Not applicableUs
Aluminum HydroxideGel320 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralAtlantic Biologicals Corps.2005-02-01Not applicableUs
Derma GranOintment.275 g/100gTopicalMckesson Medical Surgical2013-11-12Not applicableUs
DermadroxOintment1.356 g/113gTopicalGeritrex Llc2013-01-30Not applicableUs
Dermagran OintmentOintment0.275 %TopicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
AlternaGelJ&J-Merck
Alu-Cap3M
AmphojelWyeth
Brand mixtures
NameLabellerIngredients
Acid Gone AntacidMajor
Acid Gone Antacid Extra StrengthMajor
Acidex Tc Oral SuspensionGen Drug Company Ltd.
Advanced Antacid CherryMc Kesson
Advanced Antacid Regular StrengthSunmark (Mckesson)
Ahc Premium Intense Contour BalmCarver Korea Co.,Ltd.
Alka Phenyl TabDuchesnay Inc.
Alka Phenylbutazone TabPro Doc Limitee
AlmaconeRugby
Almacone Antacid AntigasRugby
Almacone Double StrengthRugby
Almagel Plus SusLaboratoire Atlas Inc
Aluminum Hydroxide and Magnesium CarbonateSimpex Pharma Pvt. Ltd
Aluminum Hydroxide, Magnesium Hydroxide, SimethiconeLLC Federal Solutions
AlumoxGuardian Drug Company
Amphojel 500 SuspensionAxcan Pharma
Amphojel Plus SuspensionAxcan Pharma
AntacidWalgreen
Antacid - Alumina and Magnesia Oral Suspension USPD.C. Labs Limited
Antacid & AntigasGericare Pharmaceuticals
Antacid and AntigasRij Pharmaceutical Corporation
Antacid Anti-gasCvs Health
Antacid AntigasSelect Brand
Antacid Antigas Maximum StrengthSelect Brand
Antacid Antigas Maximum Strength MintCvs Health
Antacid Cherry FlavoredRij Pharmaceutical Corporation
Antacid Chewable TabKsl Pharmaceuticals
Antacid Double StrengthRij Pharmaceutical Corporation
Antacid Extra StrengthRite Aid
Antacid Liquid Max Strength CherryCvs Health
Antacid Liquid MintCvs Health
Antacid Liquid SuspShoppers Drug Mart Inc.
Antacid Magnesia and AluminaStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Antacid Maximum StrengthMeijer Distribution
Antacid MintSelect Brand
Antacid Mint FlavoredRij Pharmaceutical Corporation
Antacid Plus - SusWes Pak Products Ltd.
Antacid Plus AntiflatuentStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Antacid Plus AntiflatulentKsl Pharmaceuticals
Antacid Plus Antiflatulent - Alumina, Magnesia & Simethicone Oral SuspensionD.C. Labs Limited
Antacid Plus Extra StrengthJamp Pharma Corporation
Antacid Plus Gas ReliefSafeway
Antacid Plus Gas Relief Regular StrengthSafeway
Antacid Regular StrengthKroger
Antacid Regular With Anti-gasJamp Pharma Corporation
Antacid SupremeCvs Health
Antacid Supreme CherryAaron Industries, Inc.
Antacid SusKsl Pharmaceuticals
Antacid With Alumina, Magnesia Plus Simethicone Oral Suspension USPJamp Pharma Corporation
Antacid With Anti-gas Liquid Extra Strength Mint FlavourPharmetics (2011) Inc.
Antiacide Avec Antiflatulent SusTherapex Division De E Z Em Canada Inc
Antiacide SusProduits Marc O (1987) Inc., Division Of Technilab Inc.
C2 Buffered TabWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
C2 Buffered With Codeine TabWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
Careone AntacidAmerican Sales Company
Careone Antacid Regular StrengthAmerican Sales Company
Careone Liquid AntacidAmerican Sales Company
Centra Acid Plus-susTherapex Division De E Z Em Canada Inc
Centra Acid-susTherapex Division De E Z Em Canada Inc
Conrx ArEagle Distributors,Inc.
Cvs Health Extra Strength Heartburn Relief Antacid Original FlavorCvs Health
Dg Health AntacidDolgencorp
Diovol EX TabCarter Horner Corp.
Diovol Plus SuspensionChurch & Dwight Company, Inc.
EnoBelmora LLC
Equaline AntacidSupervalu
Equaline Antacid Regular StrengthSupervalu
Equate Antacid Extra StrengthWalmart Stores
Equate Antacid Maximum StrengthWalmart Stores
Equate Antacid Regular StrengthWalmart Stores
Equate Extra Strength AntacidWalmart Stores
EstomarolLaboratorios Imperiales, S.A. De C.V.
Exchange Select Antacid Regular StrengthArmy + Air Force Exchange Service
Flanax AntacidBelmora LLC
Flanax Antacid Anti-gasBelmora LLC
Foamcoat AntacidGuardian Drug Company
Gasulsol TabHerbes Universelles Inc.
GasvaLes Produits Gerbex Inc.
Gavis-care AntacidGericare Pharmaceuticals
GavisconGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc
Gaviscon Butterscotch Flavour TabletsSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.
Gaviscon Extra StrengthGlaxo Smith Kline Consumer Heathcare Lp
Gaviscon Extra Strength Butterscotch Flavoured TabletsSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.
Gaviscon Extra Strength Strawberry Fl.tabsSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.
Gaviscon Extra Strength TabletsGlaxosmithkline Inc
Gaviscon Regular StrengthGlaxo Smith Kline Consumer Heathcare Lp
Gaviscon TabletsGlaxosmithkline Inc
Gaviscon Tablets - Butterscotch and Fr.fl.Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.
Gaviscon Tabs Extra StrengthSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.
GelusilWell Spring Pharmaceutical Corporation
Gelusil Antacid & Anti-gasBoyd Pharmaceuticals Inc.
Gelusil Extra Strength LiqWarner Lambert Canada Inc.
Gelusil Extra Strength TabletsWell Spring Pharmaceutical Corporation
Gelusil Liquid SusPfizer Canada Inc., Consumer Healthcare Division
Gelusil Maximum StrengthWell Spring Pharmaceutical Corporation
Geri-lanta Antacid AntigasGericare Pharmaceuticals
Geri-lanta Maximum StrengthGericare Pharmaceuticals
Geri-mox Antacid AntigasGericare Pharmaceuticals
Geri-mox Max CherryGericare Pharmaceuticals
Good Neighbor Pharmacy AntacidAmerisource Bergen
Good Neighbor Pharmacy Antacid Extra StrengthAmerisource Bergen
Good Sense AntacidL. Perrigo Company
Good Sense Antacid Maximum StrengthL. Perrigo Company
Good Sense Antacid Regular StrengthL. Perrigo Company
Harris Teeter AntacidHarris Teeter
Harris Teeter Antacid Maximum StrengthHarris Teeter
Harris Teeter Antacid Regular StrengthHarris Teeter
Health Mart AntacidMc Kesson
Healthy Accents AntacidDza Brands,
Healthy Accents MaldroxalDza Brands,
Heartburn ReliefVita Health Products Inc
Heartburn Relief - TabStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Indigel Plus LiquidProduits Francais Labs Inc.
InonSato Pharmaceutical
Isa Knox Ageless Serum Makeup Base 10Lg Household & Health Care Ltd.
Isaknox Ageless Serum Blemish BalmLg Household & Health Care Ltd.
Isaknox Ageless Serum Moist Pearl BaseLg Household & Health Care Ltd.
Leader Antacid Extra StrengthCardinal Health
Leader Antacid Maximum StrengthCardinal Health
Leader Antacid Regular StrengthCardinal Health
Leader Antacidregular Strength Regular StrengthRemedy Repack
Maalox Advanced Antacid & AntigasNovartis
Maalox Advanced Extra Strength Antacid & AntigasNovartis
Maalox Advanced Maximum Strength CherryNovartis
Maalox Advanced Maximum Strength MintNovartis
Maalox Advanced Maximum Strength Wild BerryNovartis
Maalox Advanced Regular Strength MintNovartis
Maalox AntacidPhysicians Total Care, Inc.
Maalox Plus Extra Strength (cherry)Rhone Poulenc Rorer
Maalox Plus Extra Strength TabletsNovartis
Maalox Plus Suspension Extra StrengthRhone Poulenc Rorer
Maalox Plus Suspension FlavourNovartis
Maalox Plus TabRhone Poulenc Rorer
Maalox Plus TabletsNovartis
Maalox Plus Tablets Lemon FlavourRhone Poulenc Rorer
Maalox Plus Tablets Mint FlavourRhone Poulenc Rorer
Maalox SuspensionNovartis
Maalox TabletRhone Poulenc Rorer
Maalox TabletsNovartis
Maalox Tablets Cherry FlavourCiba Self Medication
Maalox Tablets Mint FlavourCiba Self Medication
Maalox Tc SuspensionRhone Poulenc Rorer
Maalox Tc TabletRhone Poulenc Rorer
Mag-ALCardinal Health
Mag-AL LiquidPharmaceutical Associates, Inc.
Mag-AL PlusPharmaceutical Associates, Inc.
Mag-AL Plus XsPharmaceutical Associates, Inc.
MagsilFortune Pharmacal Company Limited
Maximum Strength AntacidMc Kesson
Maximum Strength Antacid Anti GasPublix Supermarkets, Inc.
Maximum Strength Antacid MintCvs Health
Medi Hydro Dp Bb CreamMbg Inc (Korea Institute of Science Development)
Medique Alamag PlusUnifirst First Aid
Mi-acid Maximum StrengthMajor
Mi-acid Regular StrengthMajor
MintoxMajor
Mintox Maximum StrengthMajor
Mintox Plus TabsMajor
Mucaine - SusAurium Pharma Inc
Mylanta Liquid Extra Strength SusPfizer Canada Inc., Consumer Healthcare Division
Mylanta Liquid Regular Strength SusPfizer Canada Inc., Consumer Healthcare Division
Mylanta Maximum Strength Classic FlavorInfirst Healthcare
Mylanta Maximum Strength Vanilla Caramel FlavorInfirst Healthcare
Mylanta Plain Liq Double StrengthParke Davis Division, Warner Lambert Canada Inc.
Mylanta Plain Liq Double Strength SusPfizer Canada Inc., Consumer Healthcare Division
Mylanta Tablets Double StrengthMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Mylanta Tablets Regular StrengthMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Neutralca S SusDesbergers LtÉe, Division Of Technilab Inc.
Neutralca S TabDesbergers LtÉe, Division Of Technilab Inc.
Phenylone Plus TabMedic Laboratory LtÉe
PMS-alumina Mag and Simethicone SusPharmascience Inc
Rafton Tablets - Fruit FlavourFerring Pharmaceuticals
Regular Strength AntacidChain Drug Marketing Association
Regular Strength Antacid Anti GasPublix Supermarkets, Inc.
Regular Strength Antacid MintCvs Health
Rexall Antacid AdvancedDolgencorp
Ri MoxRij Pharmaceutical Corporation
Riginic Antacid LiquidRij Pharmaceutical Corporation
Rulox RegularRugby
Rx Act Antacid Extra StrengthH.E.B.
Rx Act Antacid Regular StrengthH.E.B.
Signature Care Antacid Plus Gas ReliefSafeway
Smart Sense AntacidKmart Corporation
Sohmed Acid ReducerSOHM Inc.
Sooryehan Onbit Essence Foundation 21Lg Household & Health Care Ltd.
Spasmo Nil TabDuchesnay Inc.
StomaaxTheralab Inc.
Stomaax PlusLaboratoire Atlas Inc
Stratuscare Antacid and AntigasStratus Pharmaceuticals
Stratuscare Antacid and Antigas Regular StrengthStratus Pharmaceuticals
Sunmark AntacidMc Kesson
Sunmark Antacid Extra StrengthMc Kesson
Sunmark Antacid Maximum StrengthMc Kesson
Sunmark Antacid Maximum Strength CherryMc Kesson
Topcare AntacidTopco Associates
Topcare Antacid Maximum StrengthTopco Associates
Topcare Antacid Plus Anti GasTopco Associates
Topcare Antacid Regular StrengthTopco Associates
Univol SuspensionCarter Horner Corp.
Up and Up Antacid Anti Gas Regular StrengthTarget Corporation.
Categories
UNII5QB0T2IUN0
CAS number21645-51-2
WeightAverage: 78.0036
Monoisotopic: 77.989757403
Chemical FormulaAlH3O3
InChI KeyWNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) ion trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]
Pharmacology
Indication

For relief of heartburn and acid indigestion.

Structured Indications
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.

Mechanism of action

Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Related Articles
Absorption

Approximately 17-30% of the aluminum chloride formed is absorbed.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Not metabolized.

Route of elimination

Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.

Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminum hydroxide.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AcepromazineAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
AlfacalcidolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAluminum hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
AmphetamineAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AtazanavirAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
BenzphetamineAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aluminum hydroxide.Approved
BL-1020Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
CalcidiolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcipotriol.Approved
CalcitriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminum hydroxide.Withdrawn
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
ChlorphentermineAluminum hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorpromazineAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineAluminum hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CholecalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
CinoxacinAluminum hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CiprofloxacinAluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.Approved
DasatinibAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aluminum hydroxide.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aluminum hydroxide.Approved
DemeclocyclineAluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminum hydroxide.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
DexmethylphenidateAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aluminum hydroxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aluminum hydroxide.Approved
DihydrotachysterolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.Approved
Dipotassium phosphateAluminum hydroxide can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.Approved
DoxercalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol.Approved
DoxycyclineAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Aluminum hydroxide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aluminum hydroxide.Approved
EnoxacinAluminum hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninThe bioavailability of Equilenin can be decreased when combined with Aluminum hydroxide.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Aluminum hydroxide.Approved
ErgocalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Aluminum hydroxide.Approved
EthambutolAluminum hydroxide can cause a decrease in the absorption of Ethambutol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Ferric CarboxymaltoseAluminum hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateAluminum hydroxide can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminum hydroxide.Approved
FleroxacinAluminum hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved
FlumequineAluminum hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved
FluphenazineAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone PropionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Aluminum hydroxide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GatifloxacinAluminum hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GemifloxacinAluminum hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinAluminum hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Aluminum hydroxide.Investigational
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
HydroxyamphetamineAluminum hydroxide may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum hydroxide.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
IronAluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAluminum hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAluminum hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aluminum hydroxide.Approved
LevofloxacinAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.Approved
LisdexamfetamineAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinAluminum hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Aluminum hydroxide.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aluminum hydroxide.Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Aluminum hydroxide.Approved, Investigational
MephentermineAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MequitazineAluminum hydroxide can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.Approved
MesoridazineAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethotrimeprazineAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Methylene blueAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.Experimental
MinocyclineAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Aluminum hydroxide is combined with Misoprostol.Approved
MMDAAluminum hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MoricizineAluminum hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
MoxifloxacinAluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAluminum hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Aluminum hydroxide.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
NorfloxacinAluminum hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinAluminum hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl estroneThe bioavailability of Oleoyl estrone can be decreased when combined with Aluminum hydroxide.Investigational
OxytetracyclineAluminum hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.Approved
ParicalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.Approved
PefloxacinAluminum hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aluminum hydroxide.Approved
PerphenazineAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Potassium CitratePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Vet Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Aluminum hydroxide.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Aluminum hydroxide.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Aluminum hydroxide.Experimental
ProchlorperazineAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrineAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Aluminum hydroxide.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Aluminum hydroxide.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Aluminum hydroxide.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aluminum hydroxide.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aluminum hydroxide.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
RosoxacinAluminum hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Sodium CitrateSodium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Sodium glycerophosphateAluminum hydroxide can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateAluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
SparfloxacinAluminum hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Aluminum hydroxide.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Aluminum hydroxide.Approved
TemafloxacinAluminum hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiethylperazineAluminum hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Tiludronic acidThe serum concentration of Tiludronate can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aluminum hydroxide.Approved
TolevamerThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Aluminum hydroxide.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
TriethylenetetramineAluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAluminum hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
UbidecarenoneThe serum concentration of Coenzyme Q10 can be decreased when it is combined with Aluminum hydroxide.Experimental
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Vitamin CVitamin C can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Nutraceutical
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Food InteractionsNot Available
References
Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.

US4915930
General ReferencesNot Available
External Links
ATC CodesA02AB01
AHFS Codes
  • 56:04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedPreventionFlu caused by Influenza1
1CompletedPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections6
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentToxic Shock Syndrome Staphylococcal1
1RecruitingBasic ScienceGastroesophageal Reflux Disease1
1RecruitingPreventionExposure to Hepatitis B Virus1
1WithdrawnPreventionCoronavirus (SARS-CoV)1
1WithdrawnPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1WithdrawnPreventionSevere Acute Respiratory Syndrome1
1, 2CompletedPreventionFlu caused by Influenza3
2CompletedNot AvailableAcid Reflux Disease / GERD / Heartburn / Regurgitation1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableUnknown StatusPreventionPeptic Ulcers / Ulcer Complications1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral600 mg
GelOral320 mg/5mL
LiquidOral320 mg/5mL
OintmentTopical.275 g/100g
OintmentTopical1.356 g/113g
OintmentTopical0.275 %
SolutionOral
PowderOral
Tablet, chewableOral
TabletOral
GranuleOral
CreamTopical
LiquidTopical
LiquidOral
SuspensionOral
TabletOral; Other
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
KingdomChemical entities
Super ClassInorganic compounds
ClassMixed metal/non-metal compounds
Sub ClassPost-transition metal oxoanionic compounds
Direct ParentPost-transition metal hydroxides
Alternative ParentsPost-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
SubstituentsPost-transition metal hydroxide / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular FrameworkNot Available
External Descriptorsaluminium hydroxides (CHEBI:33130 )
Drug created on August 09, 2010 11:11 / Updated on June 11, 2017 21:02